G. Illei

发表

Measurement of fatigue in systemic lupus erythematosus: a systematic review.

M. Petri, M. Liang, J. Aviña-Zubieta, 2007, Arthritis and rheumatism.

MicroRNAs as biomarkers in rheumatic diseases

G. Illei, I. Alevizos, 2010, Nature Reviews Rheumatology.

Deep sequencing of short RNAs reveals novel microRNAs in minor salivary glands of patients with Sjögren's syndrome.

G. Illei, S. Jang, I. Alevizos, 2012, Oral diseases.

Identification and characterization of circulating human transitional B cells.

P. Lipsky, G. Illei, G. Sims, 2005, Blood.

Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus

Michael A. Smith, G. Illei, J. Ratchford, 2021, Science Translational Medicine.

Transfer of the AQP1 cDNA for the correction of radiation-induced salivary hypofunction.

James B. Mitchell, G. Illei, C. Van Waes, 2006, Biochimica et biophysica acta.

Use of a novel virus detection assay to identify coronavirus HKU1 in the lungs of a hematopoietic stem cell transplant recipient with fatal pneumonia

G. Illei, J. Cohen, J. Gea-Banacloche, 2011, Transplant infectious disease : an official journal of the Transplantation Society.

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

P. Lipsky, G. Illei, T. Fleisher, 2010, Arthritis and rheumatism.

Novel approaches in the treatment of lupus nephritis

G. Illei, L. Czirják, 2001, Expert opinion on investigational drugs.

Immune reactivity after adenoviral-mediated aquaporin-1 cDNA transfer to human parotid glands.

G. Illei, J. Chiorini, B. Baum, 2017, Oral diseases.

Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions

P. Lipsky, G. Illei, A. Grammer, 2003 .

A Genome-Wide Association Study Establishes Muliple Susceptibility Loci for Sjogren's Syndrome

P. Gaffney, R. Jonsson, Hongzhe Li, 2012 .

Exosomes from human saliva as a source of microRNA biomarkers.

G. Illei, R. Star, I. Alevizos, 2010, Oral diseases.

A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis.

G. Illei, D. Wallace, S. Manzi, 2003, Arthritis and rheumatism.

Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions.

P. Lipsky, G. Illei, A. Grammer, 2003, The Journal of clinical investigation.

Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis

G. Illei, A. Steinberg, D. Boumpas, 2001, Annals of Internal Medicine.

Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies.

G. Illei, A. Steinberg, D. Parkin, 2002, Arthritis and rheumatism.

LNA-anti-miR-150 ameliorated kidney injury of lupus nephritis by inhibiting renal fibrosis and macrophage infiltration

G. Illei, J. Pi, J. Kopp, 2019, Arthritis research & therapy.

Establishment of Functional Acinar-like Cultures from Human Salivary Glands

G. Illei, S. Jang, I. Alevizos, 2015, Journal of dental research.

Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren’s syndrome

P. Gaffney, R. Jonsson, B. Segal, 2013, Nature Genetics.

Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus

G. Illei, D. Farge, T. Martin, 2011, Annals of the rheumatic diseases.

Aquaporin-1 gene transfer to correct radiation-induced salivary hypofunction.

G. Illei, Shuying Liu, B. Baum, 2009, Handbook of experimental pharmacology.

Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus

Michael A. Smith, G. Illei, A. Remaley, 2020, Arthritis & rheumatology.

Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab

G. Illei, E. Morand, R. Tummala, 2018, Annals of the rheumatic diseases.

Autoreactive IgE Is Prevalent in Systemic Lupus Erythematosus and Is Associated with Increased Disease Activity and Nephritis

G. Illei, Christophe Pellefigues, B. Dema, 2014, PloS one.

Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy.

G. Illei, J. Balow, H. Austin, 2009, Journal of the American Society of Nephrology : JASN.

Lupus Erythematosus Function in Patients with Active Systemic T Regulatory CellhighCD 25 + Deficient CD 4

P. Lipsky, G. Illei, Cheryl H Yarboro, 2007 .

The Met66 allele of the functional Val66Met polymorphism in the brain-derived neurotrophic factor gene confers protection against neurocognitive dysfunction in systemic lupus erythematosus

P. Lipsky, G. Illei, D. Goldman, 2006, Annals of the rheumatic diseases.

Response of peripheral blood mononuclear cells from lupus patients to stimulation by CpG oligodeoxynucleotides.

K. Ishii, G. Illei, D. Klinman, 2003, Rheumatology.

Fludarabine Pharmacokinetics after Subcutaneous and Intravenous Administration in Patients with Lupus Nephritis

G. Illei, A. Burstein, F. Pucino, 2001, Pharmacotherapy.

The role of immune ablation and stem cell transplantation in severe SLE.

G. Illei, S. Pavletic, 2005, Best practice & research. Clinical rheumatology.

Blood stem cells as therapy for severe lupus

G. Illei, S. Pavletic, 2005, Expert opinion on biological therapy.

Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases.

P. Lipsky, G. Illei, 2000, Current opinion in immunology.

LocaL administration of soLuBLe cd40:fc to the saLivary gLands of non-oBese diaBetic mice does not ameLiorate autoimmune disease

G. Illei, P. Tak, J. Chiorini, 2012 .

94 – Cytokine therapy

G. Illei, G. Uzel, J. Steinke, 2008 .

Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis.

G. Illei, J. Tisdale, D. Boumpas, 2007, Rheumatology.

Dubois' Lupus Erythematosus, 6th Edition

G. Illei, F. Pucino, D. Dang, 2002 .

Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells.

G. Illei, A. Barrett, M. Bishop, 2004, Blood.

Cytokines in Sjögren's syndrome.

G. Illei, P. Tak, N. Roescher, 2009, Oral diseases.

Elevated interleukin-10: a new cause of dyslipidemia leading to severe HDL deficiency.

W. Wilson, G. Illei, R. Shamburek, 2015, Journal of clinical lipidology.

Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis.

T. Mayadas, G. Illei, Hong-shan Wang, 2012, Immunity.

Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability.

P. Lipsky, G. Illei, E. Tackey, 2004, Arthritis and rheumatism.

Association of bone morphogenetic protein 6 with exocrine gland dysfunction in patients with Sjögren's syndrome and in mice.

G. Illei, J. Chiorini, M. Weller, 2013, Arthritis and rheumatism.

Novel approaches in the treatment of lupus nephritis

G. Illei, J. Klippel, 1998, Lupus.

an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.

K. Kalunian, G. Illei, M. Khamashta, 2016 .

Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE

Michael A. Smith, G. Illei, W. White, 2018, Lupus Science & Medicine.

Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus

P. Lipsky, G. Illei, Y. Shirota, 2012, Annals of the rheumatic diseases.

IL-10 Improves Skin Disease and Modulates Endothelial Activation and Leukocyte Effector Function in Patients with Psoriatic Arthritis1

G. Illei, I. McInnes, C. Prussin, 2001, The Journal of Immunology.

C HAPTER 8 Summary and Discussion Experience with Experimental Biological Treatment a nd Local Gene Therapy of Sjögren ’ s Syndrome : Implications for Exocrine Pathogenesis and Treatmen t ( Continued )

G. Illei, P. Tak, B. Baum, 2017 .

Experience with experimental biological treatment and local gene therapy in Sjögren’s syndrome: implications for exocrine pathogenesis and treatment

G. Illei, P. Tak, B. Baum, 2006, Annals of the rheumatic diseases.

circMTND5 Participates in Renal Mitochondrial Injury and Fibrosis by Sponging MIR6812 in Lupus Nephritis

G. Illei, J. Pi, J. Kopp, 2022, Oxidative medicine and cellular longevity.

Different types of false positive anti-HIV reactions in patients on haemodialysis.

G. Illei, G. Füst, M. Dierich, 1989, Immunology letters.

Transfusion‐associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus

G. Illei, J. Tisdale, D. Boumpas, 2003, Transfusion.

Transient detection of E1‐containing adenovirus in saliva after the delivery of a first‐generation adenoviral vector to human parotid gland

G. Illei, Shuying Liu, J. Chiorini, 2010, The journal of gene medicine.

Peptide-based ELISAs are not sensitive and specific enough to detect muscarinic receptor type 3 autoantibodies in serum from patients with Sjögren's syndrome

G. Illei, J. Chiorini, A. Kingman, 2010, Annals of the rheumatic diseases.

Genetic association between methyl-CpG binding protein 2 (MECP2) and primary Sjögren's syndrome

R. Jonsson, A. Bolstad, G. Illei, 2010, Annals of the rheumatic diseases.

Effect of serotype 5 adenoviral and serotype 2 adeno- associated viral vector-mediated gene transfer to salivary glands on the composition of saliva.

G. Illei, Jianghuai Wang, B. Baum, 2006, Human gene therapy.

Sensitive and robust luminescent profiling of anti-La and other autoantibodies in Sjögren's syndrome

G. Illei, M. Iadarola, J. Baraniuk, 2009, Autoimmunity.

Cytokines in Sjögren's syndrome: potential therapeutic targets

G. Illei, P. Tak, N. Roescher, 2010, Annals of the rheumatic diseases.

UvA-DARE ( Digital Academic Repository ) Cytokines in Sjogren ' s syndrome : potential therapeutic targets

G. Illei, P. Tak, N. Roescher, 2010 .

The expression of APRIL in Sjogren's syndrome: aberrant expression of APRIL in the salivary gland.

G. Illei, P. Tak, N. Roescher, 2012, Rheumatology.

The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity.

D. Gladman, M. Abrahamowicz, C. Gordon, 2004, Arthritis and rheumatism.

Assessment of ovarian function with anti-Müllerian hormone in systemic lupus erythematosus patients undergoing hematopoietic stem cell transplant.

G. Illei, J. Segars, A. Decherney, 2009, Fertility and sterility.

RAPID VISION LOSS ASSOCIATED WITH FLUDARABINE ADMINISTRATION

G. Illei, D. Cunningham, S. Pavletic, 2010, Retina.

Effect of Soluble ICAM-1 on a Sjögren's Syndrome-like Phenotype in NOD Mice Is Disease Stage Dependent

G. Illei, P. Tak, J. Chiorini, 2011, PloS one.

Diagnosis and treatment of vasculitis of the central nervous system in a patient with systemic lupus erythematosus

G. Illei, N. Patronas, Janine A. Smith, 2006, Nature Clinical Practice Rheumatology.

Biomarkers in systemic lupus erythematosus

P. Lipsky, G. Illei, 2004, Current rheumatology reports.

Biomarkers in systemic lupus erythematosus: II. Markers of disease activity.

P. Lipsky, G. Illei, E. Tackey, 2004, Arthritis and rheumatism.

Early responses to adenoviral-mediated transfer of the aquaporin-1 cDNA for radiation-induced salivary hypofunction

James B. Mitchell, G. Illei, Shuying Liu, 2012, Proceedings of the National Academy of Sciences.

G. Illei, S. Hasni, A. Golding, 2014 .

Can quantified salivary gland scintigraphy results aid diagnosis of patients with sicca symptoms?

G. Illei, N. Roescher, 2008, Nature Clinical Practice Rheumatology.

Development of a gene transfer-based treatment for radiation-induced salivary hypofunction.

G. Illei, Shuying Liu, J. Chiorini, 2010, Oral oncology.

Late responses to adenoviral-mediated transfer of the aquaporin-1 gene for radiation-induced salivary hypofunction

G. Illei, Shuying Liu, J. Chiorini, 2016, Gene Therapy.

Lymphocyte depletion with fludarabine in patients with psoriatic arthritis: clinical and immunological effects

G. Illei, J. Davis, D. Boumpas, 2003, Annals of the rheumatic diseases.

Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis.

G. Illei, I. McInnes, C. Hitchon, 2000, Arthritis and rheumatism.

AB0189 Geographic Differences in Demographics, Clinical Characteristics, and Standard of Care in Multinational Studies of Patients with Moderate to Severe Sle

G. Illei, L. Wang, R. Furie, 2015 .

Temporal changes in salivary glands of non-obese diabetic mice as a model for Sjögren's syndrome.

G. Illei, P. Tak, J. Chiorini, 2012, Oral diseases.

Pathogenesis of Sjögren's syndrome

G. Illei, N. Nikolov, 2009, Current opinion in rheumatology.

Helicobacter pylori and autoimmune diseases.

G. Illei, S. Hasni, A. Ippolito, 2011, Oral diseases.

Biologic treatments for systemic rheumatic diseases.

G. Illei, Y. Shirota, N. Nikolov, 2008, Oral diseases.

The Majority of MicroRNAs Detectable in Serum and Saliva Is Concentrated in Exosomes

G. Illei, I. Alevizos, M. Tandon, 2012, PloS one.

Identification of parotid salivary biomarkers in Sjogren's syndrome by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry and two-dimensional difference gel electrophoresis.

G. Illei, G. Hoehn, T. Hart, 2006, Rheumatology.

TACI-Fc gene therapy improves autoimmune sialadenitis but not salivary gland function in non-obese diabetic mice.

G. Illei, P. Tak, J. Chiorini, 2012, Oral diseases.

Targeting the Ca2 + Sensor STIM1 by Exosomal Transfer of Ebv-miR-BART13-3p is Associated with Sjögren's Syndrome

G. Illei, I. Ambudkar, P. Pérez, 2016, EBioMedicine.

Ebv-miR-BART13-3p is Associated with Sjögren's Syndrome

G. Illei, I. Ambudkar, P. Pérez, 2016 .

miR-150 promotes renal fibrosis in lupus nephritis by downregulating SOCS1.

G. Illei, C. Zheng, P. Pérez, 2013, Journal of the American Society of Nephrology : JASN.

Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures.

G. Illei, E. Shevach, D. Tran, 2009, Blood.

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

K. Kalunian, G. Illei, M. Khamashta, 2016, Annals of the rheumatic diseases.

Urinary exosomal transcription factors, a new class of biomarkers for renal disease.

G. Illei, M. Cho, R. Star, 2008, Kidney international.

MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjögren's syndrome.

G. Illei, I. Alevizos, Stefanie Alexander, 2011, Arthritis and rheumatism.

BASOPHILS AND THE T HELPER 2 ENVIRONMENT CAN PROMOTE THE DEVELOPMENT OF LUPUS NEPHRITIS

G. Illei, E. Daugas, J. Rivera, 2010, Nature Medicine.

The percentage of FoxP3+Helios+ Treg cells correlates positively with disease activity in systemic lupus erythematosus.

G. Illei, E. Shevach, S. Hasni, 2013, Arthritis and rheumatism.

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus

K. Kalunian, G. Illei, M. Khamashta, 2017, Arthritis & rheumatology.

Abnormal differentiation of memory T cells in systemic lupus erythematosus.

P. Lipsky, G. Illei, R. Hodes, 2006, Arthritis and rheumatism.

Distinct T Cell/Renal Tubular Epithelial Cell Interactions Define Differential Chemokine Production: Implications for Tubulointerstitial Injury in Chronic Glomerulonephritides

G. Illei, I. McInnes, D. Boumpas, 2000, The Journal of Immunology.

CD40 ligand-activated human monocytes amplify glomerular inflammatory responses through soluble and cell-to-cell contact-dependent mechanisms.

G. Illei, I. McInnes, D. Boumpas, 1999, Journal of immunology.

Deficient CD4+CD25high T Regulatory Cell Function in Patients with Active Systemic Lupus Erythematosus1

P. Lipsky, G. Illei, Cheryl H Yarboro, 2007, The Journal of Immunology.

X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome

P. Gaffney, R. Jonsson, K. Siminovitch, 2015, Arthritis & rheumatology.

Effect of pepsin treatment on the HIV envelope and core antigens.

G. Illei, G. Füst, E. Újhelyi, 1989, AIDS.

Information on Author's Funding Support Omitted From the Article by Golding et al (Arthritis Rheum, November 2013)

G. Illei, E. Shevach, S. Hasni, 2014 .

Errors in Author Name and Author Affiliations in Reply Letter by Golding et al (Arthritis Rheumatol, May 2014)

G. Illei, S. Hasni, A. Golding, 2014 .

Gelatinase expression and activity in the synovium and skin of patients with erosive psoriatic arthritis.

G. Illei, C. Hitchon, H. El-Gabalawy, 2002, The Journal of rheumatology.

MicroRNAs in Sjögren's syndrome as a prototypic autoimmune disease.

G. Illei, I. Alevizos, 2010, Autoimmunity reviews.

Granulocytic invasion of the central nervous system after hematopoietic stem cell transplantation for systemic lupus erythematosus.

P. Lipsky, G. Illei, J. Butman, 2006, Haematologica.

Hematopoietic stem cell transplantation in autoimmune diseases: is the glass half full or half empty?

G. Illei, 2006, Arthritis and rheumatism.

Vasculitis associated with primary rheumatologic diseases.

G. Illei, D. Boumpas, C. Danning, 1998, Current opinion in rheumatology.

The Non-Muscle Myosin Heavy Chain 9 Gene (MYH9) Is Not Associated with Lupus Nephritis in African Americans

C. Winkler, M. Petri, J. Reveille, 2010, American Journal of Nephrology.

Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus.

B. Volpe, P. Lipsky, S. Marenco, 2006, Arthritis and rheumatism.

Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.

Zeruesenay Desta, David A Flockhart, G. Illei, 2004, Arthritis and rheumatism.

IL 2 RA and IL 7 RA genes confer susceptibility for multiple sclerosis in two independent European populations

F. Holsboer, G. Illei, E. Remmers, 2008 .

Monocyte response to Th1 stimulation and effector function toward human mesangial cells are not impaired in patients with lupus nephritis.

G. Illei, D. Boumpas, T. Kuroiwa, 2003, Clinical immunology.

The IRF5-TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share.

P. Gaffney, M. Weirauch, R. Jonsson, 2014, Human molecular genetics.

Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus

G. Illei, M. Khamashta, J. Merrill, 2018, Lupus Science & Medicine.

Results of longitudinal immunological surveillance of individuals directly or indirectly infected by a single HIV seropositive donor

D. Fuchs, G. Illei, G. Füst, 1990 .

Adrenomedullary Response to Glucagon in Patients with Primary Sjögren’s Syndrome

G. Illei, D. Goldstein, I. Alevizos, 2012, Cellular and Molecular Neurobiology.

A pilot study of the use of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography to assess the distribution of activated lymphocytes in patients with systemic lupus erythematosus.

G. Illei, S. Bacharach, J. Carrasquillo, 2004, Arthritis and rheumatism.

Use of computerized assessment to predict neuropsychological functioning and emotional distress in patients with systemic lupus erythematosus.

B. Volpe, G. Illei, B. Diamond, 2006, Arthritis and rheumatism.

Urinary markers differentially associate with kidney inflammatory activity and chronicity measures in patients with lupus nephritis

G. Illei, W. White, Lingming Zeng, 2023, Lupus Science and Medicine.

OP0291 Anifrolumab, An Anti-Interferon-Alpha Receptor Monoclonal Antibody, in Moderate To Severe Systemic Lupus Erythematosus (SLE)

G. Illei, M. Khamashta, J. Merrill, 2016 .

A High-Density Genome-Wide Association Study by the Sjogren's Genetics Network Identifies Five Novel Susceptibility Loci for Primary Sjogren's Syndrome and Confirms Association with MHC, IRF5, and BLK

R. Jonsson, B. Segal, G. Illei, 2011 .

Developing a gene therapy for Sjögren's syndrome

G. Illei, P. Tak, J. Chiorini, 2006 .

TACI-Fc gene therapy improves auto-immune sialadenitis but not salivary gland function in NOD mice

G. Illei, P. Tak, J. Chiorini, 2012 .

Predominant Glandular Cholinergic Dysautonomia in Patients With Primary Sjögren's Syndrome

G. Illei, D. Goldstein, I. Alevizos, 2015, Arthritis & rheumatology.

Helicobacter pylori and autoimmune diseases.

G. Illei, S. Hasni, A. Ippolito, 2011, Oral diseases.

Discovery and validation of novel microRNAs in Sjögren's syndrome salivary glands.

G. Illei, I. Alevizos, M. Tandon, 2014, Clinical and Experimental Rheumatology.

Long-term follow-up after lymphodepleting autologous hematopoietic cell transplantation for treatment-resistant systemic lupus erythematosus.

S. Steinberg, P. Lipsky, G. Illei, 2021, Rheumatology.

Type I interferon gene signature test–low and –high patients with systemic lupus erythematosus have distinct gene expression signatures

G. Illei, Hao Liu, K. Ranade, 2019, Lupus.

Rationale for interleukin-6 blockade in systemic lupus erythematosus

P. Lipsky, G. Illei, E. Tackey, 2004, Lupus.